CA-JUNIPER-NETWORKS
23.5.2023 09:01:35 CEST | Business Wire | Press release
Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Korian Benelux, part of a major European healthcare and long-term elderly care organization, selected Juniper’s AI-driven enterprise solutions, including wireless and wired access, to optimize network performance and reliability and deliver personalized care for its residents.
More than 11 thousand Korian employees provide care for approximately 15 thousand residents in 173 locations in The Netherlands and Belgium. Korian was drawn to the Mist AI engine with cloud-hosted operations to give its IT team greater insights into user experiences and better troubleshooting for connected medical Wi-Fi devices and phones. The real-time insights, provided by Juniper Mist Wired Assurance, Juniper Mist Wireless Assurance and the Marvis™ Virtual Network Assistant, have simplified troubleshooting at the customer, device and site level for better service quality. By leveraging Mist AI, the Juniper solution delivers customizable service levels and actionable recommendations to proactively fix issues, often before users are impacted. As a result, users experience a more reliable network infrastructure with less downtime, due to the Juniper Mist AI predictive approach. Centralized configuration and zero-touch provisioning simplify onboarding new Juniper access points and switches as facilities are updated. When Korian does a renovation, the network can be installed in one day, compared to two days with their previous wireless solution.
Staying connected to families and friends is important to the well-being of Korian’s residents and short-term recovery patients, whether they like to call, video chat or email. Residents can use tablets in their rooms to watch movies, listen to their favorite music and call the nursing staff if they need help. Voice communications are loud and clear. Families and friends have guest Wi-Fi when they come to visit.
Korian staff have fast, responsive access to their long-term care, clinical and administrative applications, so they can stay productive and focused on patient care. Smart medical devices have the more reliable connectivity necessary for Korian to provide optimal care.
The organization adopted Juniper Wireless Access Points and Wireless Assurance driven by Mist AI to deliver better resident engagement, coupled with industry-leading Wi-Fi that is both more predictable and more reliable. In addition, Juniper Networks EX Series Switches and Juniper Mist Wired Assurance provide high-performance, more secure access to the access points and other wired devices. Juniper was named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure.
Korian Benelux Group worked with Nomios, a Juniper Elite Plus partner, to create the optimal network architecture, focusing on network design, validation and testing to ensure that the Juniper solutions met strategic and technical goals.
Supporting Quotes:
“With our new network, our nursing staff have resilient access to medical and administrative applications. Computers on wheels and other smart medical equipment are always connected. Residents and their families can now easily connect to the Wi-Fi. IT has clear visibility into service level expectations and what we’re actually delivering. With Juniper Mist, we can see any Wi-Fi problems ourselves immediately, instead of waiting for nursing staff to tell us. Ultimately, we spend less time troubleshooting, and that frees up our time for more strategic priorities.”
- Christoph Van Doren, ICT Director, Korian Benelux
“Healthcare organizations are constantly looking to leverage innovative technology to deliver a high-touch experience for residents, guests and staff. The network plays a vital role at Korian by keeping its technology infrastructure healthy. It allows them to simply scale and support new applications and technologies that can assist in driving better resident outcomes and experiences.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Korian: Success Story
- 2022 Gartner Magic Quadrant for Enterprise Wired and Wireless LAN Infrastructure: View Report
- Blog: When it Comes to Wired & Wireless Access, Juniper Mist is in the Driver’s Seat
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005106/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
